Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28990391 | 1.00 | CES2 (0.53) | CES2CES1MGLLHDAC8HDAC6 | |
| SCHEMBL1317993 | 1.00 | CES2 (0.53) | CES2CES1MGLLHDAC8HDAC6 | |
| SCHEMBL3227064 | 1.00 | CES2 (0.53) | CES2CES1MGLLHDAC8HDAC6 | |
| SCHEMBL3231716 | 1.00 | CES2 (0.53) | CES2CES1MGLLHDAC8HDAC6 | |
| SCHEMBL2531344 | 1.00 | CES2 (0.53) | CES2CES1MGLLHDAC8HDAC6 | |
| SCHEMBL6250105 | 0.96 | CES2 (0.50) | CES2CES1MGLLHDAC8HDAC6 | |
| SCHEMBL3233671 | 0.96 | CES2 (0.47) | CES2CES1MGLLHDAC8HDAC6 | |
| SCHEMBL15911101 | 0.87 | NOS2 (0.44) | CES2CES1MGLLHDAC8HDAC6 | |
| SCHEMBL10482505 | 0.77 | NOS2 (0.38) | NOS2 | |
| SCHEMBL15703282 | 0.75 | CES2 (0.53) | CES2CES1MGLLHDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352453-B2 | Catalyst for olefin polymerization and production method for polar group-containing olefin-based polymers | THE UNIVERSITY OF TOKYO (JP) | 2022-06-07 | — | — | US | disclosed |
| US-20200347159-A1 | CATALYST FOR OLEFIN POLYMERIZATION AND PRODUCTION METHOD FOR POLAR GROUP-CONTAINING OLEFIN-BASED POLYMERS | THE UNIVERSITY OF TOKYO (JP) | 2020-11-05 | — | — | US | disclosed |
| EP-3708593-A1 | CATALYST FOR OLEFIN POLYMERIZATION AND PRODUCTION METHOD FOR POLAR GROUP-CONTAINING OLEFIN-BASED POLYMERS | The University Of Tokyo (JP) | 2020-09-16 | — | — | EP | disclosed |
| WO-2010009752-A1 | CURABLE SILICONE COMPOSITIONS COMPRISING CYCLO-ALKYLPHOSPHITES | MOMENTIVE PERFORMANCE MATERIALS GMBH (DE) | 2010-01-28 | — | — | WO | disclosed |
| US-4738983-A | Ethylenediamine and guanidine-derivatives | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1988-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347159-A1 | CATALYST FOR OLEFIN POLYMERIZATION AND PRODUCTION METHOD FOR POLAR GROUP-CONTAINING OLEFIN-BASED POLYMERS | POF1B, COG1, ACOX1 | CES2 1942/4885CES1 1209/4885MGLL 767/4885 |
| US-11352453-B2 | Catalyst for olefin polymerization and production method for polar group-containing olefin-based polymers | POF1B, COG1, ACOX1 | CES2 1942/4885CES1 1209/4885MGLL 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.